(NASDAQ: SXTP) 60 Degrees Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.98%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.61%.
60 Degrees Pharmaceuticals's earnings in 2026 is -$7,859,087.On average, 4 Wall Street analysts forecast SXTP's earnings for 2026 to be -$13,568,647, with the lowest SXTP earnings forecast at -$20,362,332, and the highest SXTP earnings forecast at -$6,118,667. On average, 3 Wall Street analysts forecast SXTP's earnings for 2027 to be -$1,452,343, with the lowest SXTP earnings forecast at -$1,395,388, and the highest SXTP earnings forecast at -$1,495,059.
In 2028, SXTP is forecast to generate -$1,183,390 in earnings, with the lowest earnings forecast at -$1,136,983 and the highest earnings forecast at -$1,218,196.